Abstract | In an increasing number of states and countries, cannabis now stands poised to join alcohol and tobacco as a legal drug. Quantifying the relative adverse and beneficial effects of cannabis and its constituent cannabinoids should therefore be prioritized. Whereas newspaper headlines have focused on links between cannabis and psychosis, less attention has been paid to the much more common problem of cannabis addiction. Certain cognitive changes have also been attributed to cannabis use, although their causality and longevity are fiercely debated. Identifying why some individuals are more vulnerable than others to the adverse effects of cannabis is now of paramount importance to public health. Here, we review the current state of knowledge about such vulnerability factors, the variations in types of cannabis, and the relationship between these and cognition and addiction.
For millennia, cannabis has been used medically and for religious purposes, most notably in China and India. The plant and its many constituent cannabinoids are now becoming increasingly important in modern medicine, particularly in the treatment of chronic pain and spas ticity 1 .
A much more widespread global use is for pleasure 2 : the 'stoned' experience varies widely across individuals but often includes euphoria, a heightened awareness of music and colour, and the tendencies to eat a lot and to giggle profusely 2 . Despite its pleasurable effects, most scientific research has focused on adverse consequences of using the drug, such as addiction, cognitive impairment and a possible increased risk of psychotic illness 3, 4 . How patterns of use will change as the legalization of cannabis proliferates is not known, but even a small percentage increase in the current 182 million users worldwide 5 will mean a considerable surge in absolute numbers. Are we now able to use existing evidence about the less desirable effects of cannabis use to help us to look forward to the future?
This Review aims to survey our current state of knowledge about, and then pinpoint how we should be increasing our understanding of, the effects of cannabis, given its potentially soaring future use. We first summarize the variety of unique ingredients in cannabis and outline how its use affects cognition, learning and memory in the short and long term. We survey evidence of how the effects of the drug vary according to the maturational state of the brain and then go on to discuss cannabis addiction and the mental health problems that are often related to it. Finally, we identify the important gaps in our current knowledge and look to the future in terms of both research and the current tide of changes to the legislation of cannabis.
Cannabis: a plant with many forms The multitude of names for cannabis (such as Purple Haze, Northern Lights, charas, skunk, resin, grass, marijuana and weed) in part reflects variations in genetics, growing conditions, processing, and constituent cannabinoids and terpenoids in different strains of the plant. Of the roughly 100 unique ingredients in cannabis that are called cannabinoids, most research to date has focused on the two most prominent of these: Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and cannabidiol (CBD). These two compounds seem to have a range of opposing effects on the human brain and behaviour. For example, Δ 9 -THC acutely impairs learning, produces psychosis-like effects and increases anxiety 6 , whereas CBD can enhance learning 7 and has antipsychotic 8 and anti-anxiety 9 properties in humans. When taken together, CBD may ameliorate the harmful effects of Δ 9 -THC 10, 11 . Δ 9 -THC acts as a partial agonist at cannabinoid 1 receptors (CB1Rs), whereas CBD has a complex range of pharmacological actions. For example, although CBD has low affinity for CB1R, it can attenuate CB1R agonist effects in the brain even at low concentrations (that is, providing functional antagonism of CB1R signalling) 12 . Conversely, CBD reduces the cellular re uptake and hydrolysis of the endogenous cannabinoid ('endocannabinoid' (eCB)) anandamide (AEA; also known as N-arachidonylethanolamide) in the brain 12, 13 .
1
Neuroimaging studies have documented opposing effects of Δ 9 -THC and CBD on blood oxygenation leveldependent (BOLD) signals during performance of several cognitive and emotional tasks, including the striatal response during memory retrieval and the amygdala response to fearful faces 14 . Over the past two decades, the Δ 9 -THC content of street cannabis has risen dramatically, whereas its CBD content has decreased to negligible levels. For example, in the United States, the Δ 9 -THC content of street cannabis rose from 4% in 1995 to 12% in 2014 (REF. 15 ). In Europe 16, 17 and Australia
18
, high-potency cannabis containing ~15% Δ 9 -THC and less than 0.1% CBD now dominates the market. Thus, the type of cannabis available years ago differs considerably from that sold today, limiting the relevance of older longitudinal cohort studies (for example, the New Zealand birth cohort study; see BOX 1) to the mental health and cognitive function of contemporary users. In the United States, the cannabis that the National Institute of Drug Abuse supplies to researchers for experiments generally has less than 4% Δ 9 -THC, and so findings from these experiments have limited implications for modern-day cannabis users.
Cognition, learning and memory eCBs are, in a sense, the brain's own natural cannabis system, and Δ 9 -THC and other CB1R agonists alter brain levels of eCBs 19, 20 . eCBs are neuroactive lipids that participate
Box 1 | Does cannabis affect IQ or educational attainment?
Case-control and prospective cohort studies have found associations between cannabis use and both lower IQ and lower educational attainment. But do these associations reflect any causal relationships?
Does cannabis affect IQ?
To date, there have been three large prospective cohort studies that have assessed the relationship between cannabis use and IQ.
In a New Zealand birth cohort study of 1,037 38-year-old individuals born in 1972 or 1973, persistent cannabis dependence was associated with a decline of up to 6 IQ points from that measured at the age of 7-13 years 54 . The decline was particularly evident for those who developed cannabis dependence in adolescence, and remained apparent even for those who, at the age of 38 years, used cannabis less than once a week.
By contrast, a UK birth cohort study of 2,235 15-16-year-old adolescents born in 1991 or 1992 found that cumulative cannabis use was not associated with a lower IQ compared with non-using controls when IQ measured pre-teen and various potential confounders (in particular, the adolescents' use of cigarettes and alcohol) were taken into account 163 . However, cannabis use was relatively low in this study, with only 72 adolescents reporting more than 50 lifetime cannabis exposures.
A US prospective cohort study of 3,066 17-20-year-old individuals found no difference in IQ from that measured at the age of 9-12 years between monozygotic and dizygotic twins discordant for cannabis use 164 . However, there were only 47 discordant twin pairs in which the cannabis-using twin had used cannabis frequently (more than 30 cumulative uses, and/or daily use), limiting the strength of any conclusions from this study.
The UK and US studies therefore both suggest that genetic or environmental factors drive the observed associations between lower IQ and cannabis use, although both cohorts included younger participants with fewer cannabis exposures than did the New Zealand study.
To date, all studies have relied on retrospective self-report of cannabis use, have ignored possible residual effects of the drug on IQ test performance and have not addressed the potency or variety of cannabis used (see the main article). Addressing these issues with confirmation of exposure to Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and other cannabinoids (such as cannabidiol (CBD)) using hair samples from participants may lead to more reliable and consistent findings 165 .
Does cannabis use affect educational attainment?
Several case-control and longitudinal studies have provided fairly consistent evidence of associations between adolescent cannabis use and both early school leaving and poorer educational performance [166] [167] [168] [169] . But the mechanisms producing these relationships remain hotly debated 170 . Causal explanations have posited that heavy cannabis use results in cognitive and/or motivational deficits, which in turn result in poorer educational attainment. There are many anecdotes about an 'amotivational syndrome' resulting from heavy cannabis use, and a recent positron emission tomography study demonstrated that cannabis users had reductions in striatal dopamine synthesis that correlated with a measure of amotivation 171 . Alternatively, reverse causality has been also suggested; that is, perhaps poorer educational attainment leads to cannabis use 166, 168 . However, the one study that addressed this hypothesis showed that the association between early school leaving and later cannabis use could be accounted for by cannabis use before leaving school early 166 . The other alternative is that educational attainment and cannabis use may not be causally related but instead share common risk factors 168, 170, 172 . Reported associations between cannabis use and lower educational attainment have typically been robust to adjustment for some potential confounders such as early-life factors, baseline school performance or cognitive ability, social disadvantage and parental educational achievement 167, 169 . However, the potential role of teenage behaviours that typically occur alongside cannabis use -including use of other substances and other 'risky' behaviours such as truancy -remain relatively unexplored 163, 170 . Recent analyses showed that adjusting for teenage use of other substances attenuated the association between cannabis use and school attainment 163, 173, 174 . As such, the existence of unmeasured confounds is often posited to account for the negative associations with cannabis 163, 168, 170 . Indeed, this idea is strongly supported by recent genetic studies that found no difference in early school leaving 170 or years of education 175 between both monozygotic and dizygotic twin pairs who were discordant for cannabis use 170, 175 .
Long-term potentiation (LTP). A lasting increase in the strength of neurotransmission at a synapse that is implicated in learning and memory.
Long-term depression
(LTD). An enduring decrease in the strength of neurotransmission at a synapse that is implicated learning and memory.
Episodic memory
Personal, contextualized autobiographical memory of past experiences.
Working memory
The capacity to hold information 'online' (maintenance) and manipulate it.
in a range of physiological processes including reward, motivation, emotional homeostasis, pain processing, and synaptic plasticity that contributes to learning and memory. At present, the best-characterized eCBs are AEA and 2-arachidonoylglycerol (2-AG) 21, 22 , and both of these lipids exert agonist activity at CB1Rs and CB2Rs. Owing to their lipid nature, AEA and 2-AG are not stored in vesicles but are synthesized on an 'on-demand' basis and, as such, brain eCB levels are critically reliant on the balance between evoked biosynthesis and subsequent clearance by intracellular enzyme-mediated hydrolysis. eCBs are crucial in certain forms of neuronal plasticity, and Δ 9 -THC has been shown to disrupt long-term potentiation (LTP; a model for learning and memory) and long-term depression (LTD) in preclinical studies 23 . In this section, we consider the acute and longer-term effects of cannabis on cognition, learning and memory, as well as effects potentially persisting after an individual has stopped using the drug. We also review evidence on the impact of starting cannabis use early in adolescence.
Acute effects. Acute effects are transient and seen in the time period during which the individual is intoxicated with the drug (that is, feeling 'stoned' for around 5-120 minutes when smoked). A single dose of cannabis or its main active ingredient Δ 9 -THC robustly and dose-dependently impairs working and episodic memory 24, 25 . Memory impairments occur however the drug is administered, but the onset of effect is more rapid when it is inhaled or given intravenously than when it is ingested orally. Specifically, the encoding of new memories is impaired during cannabis intoxication, and this leads to subsequent deficits in recalling these memories; by contrast, the retrieval of old memories that were consolidated when not under the influence is unaffected. Cannabis-induced deficits in working memory are seen more in the ability to manipulate information while it is 'online' (for example, when doing mental arithmetic) than in the ability to simply retain information for brief periods (for example, when remembering a telephone number before dialling it). Whereas on placebo, brain activity in the dorsolateral prefrontal cortex (DLPFC) increases linearly with the working memory load of a task, acute dosing with Δ 9 -THC prevents this load-associated increase in DLPFC activity 26 . These effects on memory are consistent with the extensive preclinical evidence of: the amnestic effects of cannabis in animal models; the high density of cannabinoid receptors in memory-associated brain regions such as the hippocampus, amygdala and PFC (FIG. 1) ; and observations that Δ 9 -THC induces disruption of plasticity (including LTP and LTD) in the hippocampus and decreases acetylcholine release in both the hippocampus and the PFC (FIG. 2a) .
Some studies report acute Δ
9
-THC-induced impairment of behavioural inhibition and increases in impulsivity, but findings on attention, decision-making and risk-taking tasks are mixed and task dependent 25, 27 . There is also some evidence that acute effects may vary depending on an individual's previous level of use of the drug. Tolerance to the memory-impairing 28 and psychomotor 29 effects of acute Δ 9 -THC have been shown in individuals who use cannabis more than once a week, probably reflecting downregulation of cortical CB1Rs 30, 31 (FIG. 2b) .
There is some evidence that acute effects of cannabis on memory depend on the particular type of cannabis ingested. Smoking cannabis with higher levels of CBD protected regular users against the acute memoryimpairing effects of Δ 9 -THC 10 . Findings in cannabisusing volunteers replicated these protective effects of CBD on Δ 9 -THC-induced acute memory impairment 11 . Indeed, CBD alone has been shown to enhance fear extinction learning in humans 7 . This further supports the notion that CBD and Δ 9 -THC may have opposing effects on some of the neural substrates of human memory 32 . A recent cross-sectional study found that CBD appeared to protect against hippocampal volume A simplified conceptualization of the major circuits implicated in reward (namely, the ventral tegmental area (VTA), nucleus accumbens (NAc) 200 and ventral pallidum (VP)) 65, 66, 201 , stimulus-response habit formation (the dorsolateral striatum (dlStr) and globus pallidus (GP)) 67 and cognition (the prefrontal cortex (PFC), hippocampus (HIPP) and amygdalar regions). Among these regions, cannabinoid 1 receptors (CB1Rs) are expressed with the following order of density [202] [203] [204] [205] [206] : HIPP ≈ basolateral amygdala (BLA) ≈ PFC > VP ≈ GP ≈ dorsolateral striatum (dlStr) > NAc > VTA ≈ bed nucleus of the stria terminalis (BNST) > central nucleus of the amygdala (CeA). Within the amygdala, CB1R expression is highest in the lateral and basolateral nuclei, with substantially lower expression in the central nucleus 205 . In the dorsal striatum, there is a comparable medial-lateral gradient of CB1R expression, with greater levels of expression evident in lateral aspects, and comparatively lesser CB1R expression is observed in the NAc 206 . The dense CB1R expression in HIPP, PFC and amygdalar regions underlies the effects of cannabis and CB1R agonists on cognitive and memory function, whereas the presence of CB1Rs within the mesocorticolimbic regions (VTA, NAc and PFC) contributes to the rewarding effects produced by cannabinoids. Nature Reviews | Neuroscience Long-term effects. Although in several countries legislation enables new studies of medical cannabis to use prospective, randomized controlled trial designs, to date studies of the neurocognitive effects of repeatedly using cannabis (that is, the long-term or chronic effects) have relied mainly on retrospective, self-reported drug use by people who choose to use cannabis recreationally, and, in most cases, illicitly. More-objective indices of drug use can be obtained through hair samples, although such analysis has limitations (for example, they are influenced Graphical summary of alterations in neurobiological function resulting from chronic exposure to cannabinoid agonists based on studies in rodents, non-human primates and humans. These collected observations should be viewed as a model of chronic cannabis exposure rather than an explicit representation of cannabis-induced alterations in human brain function. a | Acute cannabis or moderate-dose cannabinoid 1 receptor (CB1R) agonist exposure induces neurochemical events in the mesolimbic system that are similar to those produced by other drugs of abuse, including increased dopamine (DA) release and an attenuation of evoked GABA and glutamate (Glu) release in the nucleus accumbens (NAc) 109, [111] [112] [113] 207, 208 . The induced increase in opioid peptide release in the NAc 118, 119 probably also contributes to the acute rewarding effects of Δ
-tetrahydrocannabinol (Δ 9 -THC). Disruptions in cognitive function (including attention and memory impairments) probably result from: decreased acetylcholine (ACh) release in the hippocampus (HIPP) and prefrontal cortex (PFC) 209, 210 ; reduced GABA release and increased Glu release in the PFC 211 ; and increased noradrenaline (NA) release in HIPP and frontal cortical areas [124] [125] [126] . b | Chronic Δ
-THC or CB1R agonist exposure results in decreased CB1R expression and function in many brain regions. Positron emission tomography imaging of daily cannabis users has revealed considerable decreases in CB1R levels, particularly in cortical regions 30, 31 , that correlate with years of cannabis use and withdrawal, and rapidly normalize during abstinence 30, 31 . Rodent studies demonstrate regional differences in the effects of chronic Δ 9 -THC on CB1R expression and function, with rapid and profound decreases evident in the hippocampus and layer VI of the frontal cortex, smaller but still statistically significant decreases in striatal and amygdalar regions, and nonsignificant disruptions in regions such as the globus pallidus (GP) and hypothalamic nuclei 100, 101 . The pronounced deficits in cortical and hippocampal CB1R function are consistent with memory and cognitive impairments associated with chronic cannabis use in humans. In this regard, chronic adolescent Δ 9 -THC exposure results in persistent disruptions of the hippocampal and cortical signalling that is critical for proper memory and cognitive functions. Chronic Δ 9 -THC exposure also disrupts reward-related signalling mechanisms in the mesolimbic system by reducing DA cell density in the ventral tegmental area (VTA) 212 and by decreasing VTA DA cell firing and DA release in the NAc during both spontaneous and CB1R antagonist-precipitated withdrawal 114, 115 . Consistent with these observations in animal models, reduced striatal DA synthesis has been observed in human cannabis users, and this effect appears to be driven by individuals meeting cannabis use disorder criteria 116 . Together with increased stress-related signalling, such as dynorphin release in the NAc 200 and corticotropin-releasing factor (CRF) release in the amygdala 74, 75 , these deficits in mesostriatal DA function may contribute to negative affective states associated with Δ 9 -THC abstinence. Adolescent Δ 9 -THC exposure also results in persistent increases in opioid peptide gene expression and influences the mesolimbic system of rats 192, 213, 214 , possibly contributing to an increase in the rewarding effects of opiates and increased opiate consumption by these animals in adulthood [191] [192] [193] 213 . BLA, basolateral amygdala; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the amygdala; eLTD, endocannabinoid-mediated long-term depression; GluR, glutamate receptor; MOR, μ-opioid receptor; PENK, proenkephalin. 
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by hair dyes) 34 and have been rarely used in studies. Long-term impairments in memory have been reported mainly in frequent, heavy users, but confounding factors make it difficult to establish cause-effect relationships between cannabis use and changes in neuro cognitive function. Such factors include baseline cognitive function before drug use; use of other cognitively impairing drugs, such as alcohol; types of cannabis used; age at which use started; and mental health problems, including depression and cannabis addiction.
Case-control studies of non-acute effects of cannabis have produced inconsistent findings to date, but tend to mirror acute findings. The most consistently reported long-term effects in these studies are impairments in the encoding of new episodic memories, with some studies finding persistent deficits in the first few days of abstinence but little evidence of persisting deficits at 28 days after use 25 . Meanwhile, the findings for measures of working memory, attention and impulsivity are mixed. One study 35 found no difference in decision making or risk taking between cannabis users and non-users who were matched for potential mental health confounds. However, poorer decision-making accuracy in users was significantly associated with the number of symptoms of cannabis addiction.
Functional neuroimaging studies often reveal subtle differences in brain activity between chronic cannabis users and controls during performance of cognitive tasks; again, the persistence and clinical importance of these differences remain to be determined. A systematic review 36 of 43 studies concluded that chronic cannabis use may alter brain structure and function in both adult and adolescent users (particularly in the medial temporal and frontal cortices and the cerebellum). However, the findings of the mainly cross-sectional studies displayed remarkable heterogeneity, and it was not possible to infer causation. Further, deficits are most consistently observed only among heavy users -those most likely to be addicted to cannabis. Cognitive changes related to chronic exposure to cannabis or Δ 9 -THC observed in humans and in animal model studies (such as reduced inhibitory control and impaired decision making) 27, 37, 38 are implicated in the maintenance of addiction 39 , in part by impairing the reversal of behaviours related to drug acquisition or drug taking that propel continued drug use despite negative consequences. It could thus be proposed that these cognitive changes may interact with genetic vulnerability factors to increase the risk of developing cannabis addiction.
Age-dependent effects: adolescence and adulthood. The eCB system has a major role in neurodevelopmental and maturational processes including synaptic pruning and white-matter development, and these processes are especially prevalent during adolescence. As exogenous cannabinoids affect the functioning of the eCB system, it is plausible that prolonged use during adolescence disrupts the neurodevelopmental maturational processes during this period 40 . Thus, the human brain may be more vulnerable to drugs at the time when use of cannabis often begins.
Preclinical studies have shown that repeated exposure to Δ 9 -THC has a greater negative impact on the working memory, object recognition and pre-pulse inhibition of adolescent rodents than on adult rodents 40 . Chronic administration of CB1R agonists or Δ 9 -THC to adolescent rats produces persisting impairments in object recognition memory that are not seen with the same treatment in adult rats 41, 42 , as well as greater alterations in the level of expression of various hippocampal proteins (which may account for adolescent-specific memory effects) 42 . A single dose of Δ 9 -THC has also been found to result in greater acute impairments in spatial and non-spatial learning in adolescent rats than in adult rats 43 . The age-related effects of cannabis use on cognitive function may therefore be dependent on the maturational state of the neural circuits that are affected by the drug. This may reflect the fact that Δ 9 -THC induces perturbations in the crucial influence of the eCB signalling that is involved in brain development, for processes including neural proliferation, morphogenesis, neural migration and synaptogenesis [44] [45] [46] . Consistent with this interpretation were the results of a study in which Δ 9 -THC was repeatedly administered over 6 months to adolescent monkeys at doses that corresponded well to human self-administration (approximately 1-2 joints on 5 days per week). This repeated administration blunted the usual pattern of accuracy improvements on a test of spatial working memory (which matures after object working memory), but not on an object working memory task 47 . Thus, the persistent effects of Δ 9 -THC on cognition in animals are more evident when exposure coincides with the developmental stage during which cannabinoid-affected neural circuits are actively maturing.
Similarly, there is also accumulating evidence in humans that neurocognitive function and aspects of brain architecture are more disrupted by cannabis when individuals start using it during adolescence, although there is a scarcity of direct comparisons with adult users. Some structural imaging studies in adolescent and young adult cannabis users have reported decreased volume in several cortical and subcortical regions 36 , but findings across different studies vary considerably 48 . For example, although structural differences between adolescent cannabis users and controls in orbitofrontal cortex (OFC) volume have been found, smaller OFC volumes at 12 years of age were shown to predict cannabis use at 16, suggesting that differences in the OFC may be a vulnerability factor for use rather than a consequence 49 . And although smaller hippocampal volumes in cannabis users have been associated with age of onset of use, this association seems to be less consistent than does the association between reductions in the size of the hippocampus and the amount of use, suggesting that the structure of the hippocampus may be more affected by the duration and intensity of exposure rather than by early use specifically 50 . Diffusion tensor imaging (DTI) studies have found poorer white-matter integrity (indexed by both lower fractional anisotropy and higher mean diffusivity) in
Cannabis abuse
Cannabis use that is problematic for various aspects of an individual's life (for example, causing occupational, educational or social problems) or that is carried out in dangerous contexts.
Cannabis dependence
A group of severe consequences of repeated cannabis use, including tolerance to effects, withdrawal symptoms upon cessation, dysregulation of use, increased involvement with cannabis at the expense of other activities, and continued use despite the problems it causes.
adolescents who use cannabis frequently compared with control non-users 48 . Further, reductions in those indices of white-matter integrity were found to correlate with deficits in measures of neurocognitive performance.
Several functional MRI (fMRI) studies suggest that there is an increased BOLD signal in task-related areas in young cannabis users compared with non-using controls 48 . For example, Jager and colleagues 51 assessed 13-19-year-old boys who had used cannabis at least 200 times in their lives and compared them with nonusing, age-matched controls. The cannabis users showed greater activation in prefrontal regions during a working memory task than did controls. Overall, most functional imaging findings suggest that adolescent cannabis users show increased recruitment of neural resourcespotentially reflecting compensatory activity -in brain areas subserving task-related processing.
In terms of neurocognitive function, individuals who started using cannabis during adolescence have been reported to have greater deficits in visuo spatial attention 52 , verbal fluency 53 and inhibition 53 than do those who start in adulthood. Importantly, based on the Dunedin prospective cohort data, one study 54 concluded that having cannabis addiction that started during adolescence and persisted into adulthood was associated with a decline of around 8 IQ points
. However, two recent large-scale studies cast doubt on a causal explanation
.
One limitation of the studies to date assessing the effects of cannabis use on the adolescent brain is that they have focused on age (whereby onset of use before 15-17 years of age is considered to be 'early') rather than on adolescent pubertal markers or potential sensitive periods that may more accurately index the stage of brain development 55 . As the eCB system interacts with gonadal hormones, and girls typically begin puberty earlier and reach pubertal maturation earlier than boys, pubertal stage may influence findings on sex differences. The few studies looking at acute effects of cannabis or Δ 9 -THC have found little in the way of age-dependent sex differences, although such differences may exist in chronic users 25 . One study that did investigate this, however, found that a younger age of regular cannabis use onset predicted poorer memory in women but not men 56 . Surprisingly, the same study found that an earlier age of cannabis use initiation predicted better decision-making performance in both male and female cannabis users. Maturation of the PFC and its connections with the limbic system occurs earlier in girls 57 , and this difference may contribute to reported sex differences in the effects of adolescent cannabis use 25, 56 . The paucity of studies of sex differences in the effects of cannabis limits conclusions and should be addressed by future research.
Effects persisting after stopping use. Several studies of long-term effects after an individual stops using cannabis are converging to show that cognitive impairments do not persist beyond 4-6 weeks after abstinence 58, 59 . Using positron emission tomography (PET) imaging, one study 30 demonstrated that chronic cannabis users showed downregulation of cortical CB1Rs that correlated with years of use. After ~4 weeks of continuously monitored abstinence from cannabis at a secure research unit, their CB1R density returned to control levels, further supporting recovery within 4 weeks, and even, according to one recent study, after as little as 2 days 31 . Reversible downregulation of brain CB1Rs after chronic exposure to cannabis has also been shown in rodent studies 60 . Other studies of 'persisting' effects have used structural and/or functional imaging but with cross-sectional designs, different abstention intervals and a range of confounds (including group differences in comorbid alcohol use and pre-cannabis level of functioning), which make it difficult to draw any causal conclusions. Longitudinal studies are thus needed to determine whether these effects of abstinence are seen even in those starting use in adolescence 61 .
Cannabis addiction
Much research on cannabis and mental health has focused on psychosis
, although addiction is a far more common problem: we estimate that people who try cannabis are ninefold more likely to become addicted to it than to develop psychosis in their lifetime [62] [63] [64] . In this section, we introduce the concepts of cannabis addiction and withdrawal, review the rewarding effects . However, the vast majority of people who use cannabis do not develop psychotic disorders such as schizophrenia, and many people diagnosed with such disorders have never used cannabis.
More agreement is found in evidence that heavy cannabis use may mean that young people who are vulnerable to psychosis develop the disorder when they may not have otherwise done so. Converging data suggest that this may have a genetic basis, with certain polymorphisms of the gene encoding AKT1 potentially conferring risk of psychosis following smoking cannabis acutely 177 and chronically 178, 179 . The type of cannabis used has recently been found to affect the risk of psychosis: self-reported hash use, even daily, is not associated with an increased risk of psychosis, whereas self-reported daily use of skunk (which contains high levels of Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and negligible amounts of cannabidiol (CBD)) is associated with a fivefold greater chance of having schizophrenia 180 . Several studies using objective biological markers of use have shown that CBD reduces the psychosis-like effects of Δ 9 -THC 154, 181 . How cannabis interacts with the brain to increase the risk of psychosis is unclear. One confusing finding is that of reduced dopamine release in cannabis users 116 , which seems to be inconsistent with the higher levels of dopamine release observed in people with psychosis. Disruptions in the brain's endocannabinoid system, conversely, have been found in psychosis and may provide clues as to the pro-psychotic impact of cannabis. Higher levels of anandamide (AEA) in the cerebrospinal fluid have been associated with lower psychotic symptoms in individuals diagnosed with schizophrenia 182 , in individuals classified as having prodromal schizophrenia 183 who do not smoke cannabis and in cannabis users without a diagnosis of schizophrenia 107 . AEA is known to have a neuromodulatory role in the brain; thus, during prodromal or first-episode psychosis, levels of AEA may be increased to attempt to control dysregulated brain dopamine 184 . In addition, in vivo positron emission tomography imaging and post-mortem receptor autoradiography studies have consistently reported higher levels of ligand binding to cannabinoid 1 receptors in several cortical regions of people with schizophrenia 185 . Whether these alterations are part of the disease pathology or a compensatory response remains unclear, but they do suggest a molecular basis for a heightened sensitivity to cannabis of individuals with schizophrenia, and perhaps of those at risk. of cannabinoids in relation to the eCB, dopaminergic, opioid and noradrenergic neurotransmitter systems, and highlight vulnerability factors and possible treatments for cannabis addiction.
Cannabis addiction and withdrawal. The term 'addiction' is in a terminological quagmire; here, however, we define it as an acquired, chronic, relapsing disorder that is characterized by a powerful motivation to continually engage in an activity despite persistent negative consequences. Addictive drugs can all cause similar changes to brain circuits underpinning reward, salience, impulsivity, compulsivity, learning and memory 39, [65] [66] [67] , although these changes differ according to class of drug (including cannabis) 68, 69 . Clinical problems associated with cannabis use were previously diagnosed as cannabis abuse or cannabis dependence in the Diagnostic and Statistical Manual for Mental Disorders, fourth edition, text revision (DSM-IV-TR). In the most recent version (DSM-5), these categories were amalgamated into a single diagnosis of 'cannabis use disorder' (CUD), as described in BOX 3. The estimated chances of becoming addicted to cannabis after lifetime exposure is 8.9%, which is considerably lower than for cocaine (20.9%), alcohol (22.7%) or tobacco (67.5%) 64 . Nevertheless, the clinical need for treatment of cannabis addiction is substantial and increasing in North America, Europe and Oceania 5 . Across Europe, cannabis now accounts for more first-time entrants to drug treatment services than any other illicit drug 70 . A specific cannabis withdrawal syndrome -one aspect of addiction -is well recognized and affects around 50% of daily users upon cessation of use, and typically begins 1-2 days after cessation, peaks at 2-6 days and remits at 1-2 weeks 71 . Prominent symptoms include craving, sleep problems, nightmares, anger, irritability, dysphoria and nausea 72 . Cannabis withdrawal symptoms correlate with reductions in CB1R availability during acute abstinence 31 and can be alleviated by Δ 9 -THC in a dose-dependent manner 73 . Δ 9 -THC withdrawal is also associated with increased release of the stress peptide corticotropin-releasing factor (CRF) in the central nucleus of the amygdala 74, 75 . Similar increases in amygdalar CRF release are evident during withdrawal from most classes of recreational drugs (including nicotine, alcohol, psychostimulants and opiates) and contribute to negative affective states and decreased brain reward function 76 . It is therefore noteworthy that cannabis is frequently rolled with tobacco in 'joints' , and many users also smoke cigarettes
. In daily users of cannabis and tobacco, individual withdrawal effects seem to be similar for both drugs; combined withdrawal produces stronger effects than does withdrawal for either one alone 77 .
Cannabinoids and reward. Δ 9
-THC produces the effects that cannabis users seek; they report liking it and wanting more 24 . In addition, cannabis with higher Δ 9 -THC content (for example, 3.5% versus 2.0%) produces stronger reinforcement in human choice paradigms 78 . As the re inforce ment of drug use is considered to be one component in the transition from voluntary to compulsive use 67 , these findings suggest that cannabis with high Δ 9 -THC content might increase vulnerability to addiction. However, it is difficult to extrapolate these findings to modern, high-potency cannabis with ~15% Δ 9 -THC [16] [17] [18] . Recent naturalistic studies indicate that people adapt to rising Δ 9 -THC concentrations by adding less cannabis to their joints 79 and/or inhaling less smoke 80 . Nevertheless, cross-sectional data suggest that use of cannabis with high Δ 9 -THC content is associated with greater addiction severity 81 . It is therefore possible that recent increases in cannabis potency 15, 16 might have contributed to the rising demand for treatment of cannabis addiction 5, 70 .
Box 3 | Cannabis use disorder
Cannabis-related problems vary on a continuum, and it is important to define these not only for clinical diagnosis and treatment but also for research. The Diagnostic Statistical Manual of Mental Disorders, fifth edition (DSM-5) 186 has combined the definitions for 'cannabis abuse' and 'cannabis dependence' to provide criteria for the diagnosis of 'cannabis use disorder' (CUD). DSM-5 states that CUD is: "A problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by at least 2 of the [symptoms from the three lists below], occurring within a 12-month period" (REF. 186 ). Mild CUD is associated with having two or three of these symptoms, moderate CUD, with four or five symptoms, and severe CUD, with six or more symptoms. One DSM-IV criterion -concerning persistent legal problems related to cannabis use -was dropped and not included in DSM-5 because it largely reflected sociocultural factors to do with policing and law enforcement rather than cannabis use factors.
One advantage of combining abuse and dependence criteria in CUD is to provide a clearer continuum between mild and severe, because previously all cases of dependence also met criteria for abuse. Another advantage is that dependence is often a normal bodily response to a substance (for example, a prescribed pain killer) that should not to be confused with addiction (insomuch as stopping use of that pain killer does not necessarily lead to drug seeking).
Cannabis dependence symptoms from DSM-IV
The following symptoms are taken from the DSM-IV criteria for cannabis dependence 187 
:
• Cannabis is often taken in larger amounts or over a longer period than was intended • There is a persistent desire or unsuccessful efforts to cut down or control cannabis use • A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects • Important social, occupational, or recreational activities are given up or reduced because of cannabis use • Cannabis use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis • Tolerance, as defined by either [1] a need for markedly increased cannabis to achieve intoxication or desired effect or [2] a markedly diminished effect with continued use of the same amount of the substance • Withdrawal, as manifested by either [1] the characteristic withdrawal syndrome for cannabis or [2] cannabis is taken to relieve or avoid withdrawal symptoms
Cannabis abuse symptoms from DSM-IV
The following symptoms are taken from DSM-IV criteria for cannabis abuse 
Conditioned place preference
A Pavlovian conditioning procedure used to index the motivational properties of drug experience. Typically, the time spent in an environment associated with drug intoxication is compared with that spent in a neutral context.
The presence or absence of CBD in evaluations of Δ 9 -THC reward may also be relevant. One study found that people who smoked cannabis containing low levels of CBD were more prone to have their attention captured by cannabis-related stimuli than were those smoking cannabis with high CBD content 82 . This suggests that CBD could protect against addiction, as attentional bias towards drug-related stimuli correlates with craving and is sensitive to relapse-provoking manipulations 83 . However, CBD does not influence the acute reinforcing effects of cannabis or the rewarding feeling of being 'stoned' (REFS 82, 84, 85) .
The reinforcing effects of cannabinoids in animals depend on species, route of administration and experimental design. Rats will perform an operant behaviour to receive Δ 9 -THC infusions into the brain ventricular space and to receive CB1R agonist infusions into the nucleus accumbens shell and posterior ventral tegmental area 86, 87 , as with other drugs of abuse. However, there has been substantial difficulty in establishing operant intravenous Δ 9 -THC self-administration in rodents 78 , possibly owing to the prolonged pharmacokinetic effects of Δ 9 -THC that impede the establishment of discrete response-reward associations. The higher cognitive function in primates may allow for clearer discernment as to whether lever-pressing behaviour is causal for the somewhat delayed alterations in reward state resulting from intravenous administration of Δ 9 -THC. It is also possible that the aversive and motor-depressant effects of Δ 9 -THC present greater impediments to self-administration in rodents than in primates.
Consistent with the human literature, studies in rats also demonstrate that Δ 9 -THC reward is dose dependent. These effects appear to follow an inverted-U-shaped curve, whereby high-Δ 9 -THC doses are less reinforcing than medium doses. For example, as indexed using the intracranial self-stimulation (ICSS) paradigm, rewardsystem function in the rodent brain is enhanced by low doses of Δ 9 -THC 88 , whereas higher doses and morepotent CB1R agonists can decrease this function 89, 90 . Consistent with this, the rewarding effects of low doses of Δ 9 -THC or CB1R agonists in the conditioned place preference paradigm are supplanted by aversive effects at higher doses 86, 91, 92 . An inverted-U-shaped profile is consistent with data from human studies that indicate that cannabis with high Δ 9 -THC content is preferred and associated with greater addiction severity than cannabis with low Δ 9 -THC content 81 , whereas extremely potent products (such as synthetic CB1R agonists) are less addictive than 'natural' cannabis, have more negative effects and are only preferred by 7% of users 93 . In animals, CB1R antagonism produces a 'rightward' shift along this inverted-U-shaped reward-aversion dose-effect function, blocking the rewarding effects of low doses of CB1R agonists and preventing the aversive effects of high CB1R agonist doses. This underscores the bimodal effects of CB1R activity on brain reward processing. Squirrel monkeys voluntarily self-administer intravenous Δ 9 -THC 94 , and rats reliably self-administer synthetic CB1R agonists 95, 96 -actions that are prevented by CB1R antagonism. Taken together, these studies suggest that CB1R activity has a crucial role in cannabinoid reinforcement and cannabis addiction.
Similar to Δ 9 -THC and many synthetic cannabinoid agonists, eCBs exhibit agonist effects at brain CB1Rs. The eCB AEA takes its name from the Sanskrit word ananda, meaning 'bliss' . Although pharmacologically enhanced eCB signalling (for example, through the inhibition of eCB clearance) generally does not produce rewarding effects per se, persistent disruptions in eCB signalling appear to contribute to facets of drug dependence across drug classes 97, 98 . CB1R downregulation in chronic cannabis users has been reported in three studies 30, 31, 99 ; these effects subside within days to several weeks of sustained abstinence 30, 31 . Similarly, rodents chronically exposed to Δ 9 -THC or synthetic CB1R agonists exhibit a reduction in CB1R function throughout the brain 100,101 that persists for days to weeks following Δ 9 -THC treatment, followed by a functional recovery that varies between brain regions 102 . eCB-mediated forms of synaptic plasticity in the nucleus accumbens and hippocampus are abolished following exposure to Δ 9 -THC or CB1R agonists 101, 103, 104 -and this may substantially affect reward processing and memory processes mediated by these regions. Chronic exposure to Δ 9 -THC or CB1R agonists increases enzymatic clearance of AEA and reduces brain tissue AEA content in rodents 19, 105, 106 and, consistent with these data, frequent cannabis smokers exhibit decreased AEA levels in cerebrospinal fluid 107 . Although evidence is limited, serum AEA levels may be elevated in former users of the drug following prolonged cannabis abstinence 108 .
Box 4 | The gateway theory
Although cannabis is traditionally considered to be a 'soft' drug, it is widely believed to act as a 'gateway' to harder drugs such as cocaine or heroin (with harm defined in terms of detrimental effects of using that substance on the individual and on society). According to this theory, there is a sequential progression from one drug to the next (for example, cannabis leading to cocaine, and then heroin) 188 . This theory rests on evidence that use of one drug increases the likelihood of using the next drug in the 'sequence', which may be interpreted as causal if all other confounds are accounted for 188 . Evidence does support sequential progression and association between cannabis and other illicit drugs, and these effects increase with frequency of cannabis use and adolescent onset 189 . In addition, a twin study 190 suggested that these effects cannot be attributed to shared genetic or environmental factors alone. Studies in rats demonstrate that adolescent Δ 9 -tetrahydrocannabinol (Δ 9 -THC) exposure results in increased opiate consumption and facilitated learning of cocaine self-administration in adulthood [191] [192] [193] , and that the influence of adolescent Δ 9 -THC exposure on opiate reward may be transgenerational 194 . However, establishing causality remains challenging, and putative mechanisms remain speculative. For example, one possibility is that the wide availability of cannabis means that people are more likely to use it first, and this increases the chances that other illicit drugs are used because of contact with other drug users and with people selling illicit drugs 190 . This formed part of the Netherlands' rationale for the regulated sale of cannabis; incidentally, the rates of cocaine use among people who have used cannabis are lower there (22%) than in the United States (33%) 195 . Biological explanations for the gateway hypothesis are supported by evidence that exposure to Δ 9 -THC enhances the reinforcing effects of other drugs. Intriguingly, however, prior Δ 9 -THC ingestion increases self-administration of nicotine and the reinforcing effects of nicotine in rats 196 , but this does not occur with prior cocaine or heroin exposure 197, 198 . Indeed, one of the most potentially harmful and under-appreciated effects of cannabis is the 'reverse gateway': by smoking tobacco together with cannabis in 'joints', individuals may progress to nicotine addiction 160, 199 . Dopamine, opioids and noradrenaline. Human PET studies indicate that Δ 9 -THC can increase dopamine release in the striatum 109 , although to a far lesser extent than do other recreational drugs, and not in all studies 110 . In rodents, Δ 9 -THC and CB1R agonists increase the firing rate and bursting activity of ventral tegmental area dopamine neurons, resulting in dose-dependent increases in the mesocorticolimbic release of dopamine [111] [112] [113] . Conversely, withdrawal from chronic Δ 9 -THC or CB1R agonist exposure is associated with decreased firing of dopaminergic cells and decreased dopamine release in the nucleus accumbens 114, 115 . Consistent with these observations in animal models, reduced capacity to synthesize striatal dopamine was recently reported in human cannabis users, particularly among addicted individuals 116 . However, in humans, chronic cannabis exposure is not typically associated with abnormalities in striatal dopamine release or in D2 receptor expression 117 and, together with the modest dopaminergic effects of acute Δ 9 -THC, the available human data provide only weak support for dopaminergic involvement in cannabis addiction. Δ 9 -THC-induced increases in opioid peptide release 118, 119 may also contribute to the rewarding effects of cannabis. The opioid receptor antagonist naltrexone reduces Δ 9 -THC-induced increases in meso limbic dopamine release, intravenous Δ 9 -THC self-administration and intracerebroventricular CB1R agonist self-administration in rats and monkeys 120, 121 . Sixteen days of naltrexone treatment reduced self-administration and some positive subjective effects of Δ 9 -THC in humans 122 . Δ 9 -THC and other CB1R agonists stimulate noradrenergic cell firing and increase levels of noradrenaline in multiple brain regions in which the neurotransmitter can affect motivated behaviours 123 -including the nucleus accumbens, prefrontal and cerebral cortices, hippocampus and hypothalamus [124] [125] [126] . The behavioural importance of CB1R agonist-induced increases in noradrenaline release has not been carefully evaluated, although evidence suggests that such increases in noradrenaline release may contribute to the aversive (but not anxiogenic) effects of high doses of CB1R agonists 127 . For example, the aversive effects of high doses of the CB1R agonist WIN 55,212-2 (as measured in the conditioned place aversion paradigm) are reduced by attenuation of noradrenergic signalling in the nucleus accumbens, although WIN 55,212-2-induced anxiety-like behaviour (as measured on the elevated plus maze) is not reduced by these manipulations 127 .
Vulnerability factors. Irrespective of the drug constituents 81, 82 , only a minority of cannabis users become addicted; therefore, other factors must predict vulnerability. Concurrent tobacco use has been identified as a risk factor in several studies [128] [129] [130] , as have early adolescent onset and frequent (especially daily) use 128, 131 . Males typically have an earlier opportunity to use cannabis, a greater risk of addiction and a faster progression from first opportunity of use to addiction 64, 128, 129 . These findings are consistent with normative data from European treatment services: the mean age of first treatment is 24 years; the mean age at first cannabis use is 16 years; and 83% of treated individuals are male 70 . Interestingly, a 3-year prospective study of daily users found that variables related directly to cannabis use did not predict transition to addiction; more important were current factors such as living alone, coping motives and negative life events (such as having had a major financial crisis) 215 . A meta-analysis of 24 twin studies 132 suggested that genetic influences account for 55% of the vulnerability to cannabis addiction, with shared environmental factors and non-shared environmental factors accounting for much lower proportions (17.5% and 27.5%, respectively). Although isolated studies have identified specific gene variants associated with an increased risk of developing cannabis use disorder (reviewed in REF. 133 ), cannabis addiction phenotypes are likely to be polygenic, and genotypes probably overlap with those linked to substance addiction in general 134 .
Possible treatments for cannabis addiction. Cannabis addiction is not easily treated by psychological therapies 135 , and although many pharmacotherapies have been tested 136 -including antidepressants, anxiolytics, noradrenaline-reuptake inhibitors, anticonvulsants, glutamatergic modulators and CB1R agonists -none has been approved. Based on existing clinical trial data, a 12-week trial of the GABA mimetic gabapentin 137 and an 8-week trial of N-acetylcysteine 138 have shown promise for reducing cannabis use according to urine sampling during treatment. Gabapentin also improved several secondary outcomes, including withdrawal symptoms, executive function and self-reported depression 137 . CB1R agonists such as dronabinol (an oral synthetic Δ 9 -THC) 139 and nabiximols (an oral spray containing Δ 9 -THC and CBD in equal ratio) 140 attenuated cannabis withdrawal symptoms and improved treatment retention, but did not reduce cannabis use compared with placebo. These findings suggest that substitution treatments can replace Δ 9 -THC in cannabis but are not sufficient to promote abstinence from it.
Few studies have evaluated the contribution of dysregulated eCB signalling to cannabis addiction and related physiological and behavioural disruptions. However, eCBs provide important homeostatic regulation over emotional state 141 and sleep function 142 , and so it is plausible that Δ 9 -THC-induced impairment of eCB signalling contributes to the negative emotional states and sleep disturbances that are present during protracted cannabis abstinence [71] [72] [73] . Intriguingly, studies in rodents demonstrate a palliative effect of 2-AG-clearance inhibitors on the somatic symptoms of CB1R-antagonist-precipitated Δ 9 -THC withdrawal 105 . Collectively, these observations have led to the proposed use of eCB-clearance inhibitors as treatments for cannabis withdrawal, and perhaps addiction 143, 144 . Given the largely unmet clinical need, developing effective pharmacological treatments should be a top research priority.
Cannabis, anxiety and depression Like most addictions, cannabis addiction is often comorbid with other mental health problems. Epidemiological evidence indicates a possible association between regular cannabis use and the development of anxiety and depression. However, the evidence is more mixed and less consistent than that for an association between cannabis use and psychosis 62 . One recent study compared the mental health of individuals who were addicted to cannabis (according to the DSM-IV) with that of non-addicted cannabis users who had similar patterns of cannabis use. Only the addicted users had depression and anxiety problems 145 . Compared with the general population, non-addicted frequent users were more likely to show externalizing disorders (such as attention-deficit hyperactivity disorder), which were likely to have predated their cannabis use. Otherwise, these individuals were similar in terms of mental health to the general population, suggesting that cannabis contributes to mental health problems only in those who are vulnerable for other reasons.
Depression and anxiety disorders not only are associated with cannabis addiction 146 but also are predictive of whether individuals transition from use to addiction 147 . Strikingly, a high number of cases of depression and anxiety disorders were reported among obese individuals who were treated with the anti-obesity drug rimonabant, a CB1R antagonist. Many of these individuals had no prior history of these disorders 148, 149 , and so this led to the withdrawal of rimonabant from therapeutic use. These findings suggest that CB1R antagonists increase the risk of depression and/or anxiety. Moreover, pr eclinical studies have shown that mice that genetically lack CB1Rs show increased depressive-like symptoms 150 and, in wild-type mice, CBD has antidepressant effects 151 . Rodent studies have implicated the eCB system in the regulation of emotion 152 . Similarly, there are also data from rodent studies suggesting that impaired CB1R signalling leads to depression-like symptoms, and that enhancement of CB1R signalling produces antidepressant-like behavioural effects in rodents 153 .
In our own studies of young (16-24-year-old) daily cannabis users, we have found that levels of Δ 9 -THC in hair are significantly associated with self-reported levels of both depression and anxiety 154 . However, a recent epidemiological study 146 suggested that increases in self-reported depression in cannabis users are not long-lasting, as no consistent associations were found between adolescent cannabis use and depression at the age of 29 years. By contrast, the same study showed that daily cannabis use and cannabis addiction in early adulthood were associated with more than double the non-user control rate of anxiety disorders at 29 years of age. The association between cannabis use and anxiety may arise because the same factors that predispose people to use cannabis also predispose them to anxiety. Indeed, there is accumulating evidence that, in vulnerable individuals, cannabis is often 'used' to self-medicate social anxiety 155, 156 . This is interesting, as controlled studies of acute effects in humans have shown that Δ 9 -THC increases anxiety 6 , whereas CBD decreases it 9 . Furthermore, Δ 9 -THC and CBD acutely produce opposite but subtle effects on human facial affect recognition 84 and amygdala activation when viewing fearful faces 32 . The interconnectedness of cannabis use, mental health problems and cognitive functioning is important. It is inherently difficult to determine causality in the type of studies discussed above because factors besides cannabis use (for example, premorbid cognitive and emotional function) may be directly associated with risk of mental illness. Such factors could predispose an individual both to mental illness and to using cannabis 3 , and the combination of these disorders would in turn increase their impact on cognitive functioning.
Conclusions and future directions
Cannabis has been used for thousands of years for a range of medicinal purposes as well as for its desired psychological and social effects, which recreational users value. This use can, however, carry a penalty: a range of undesired effects that vary in the severity of their impact on the individual's life. Although evidence of clear causality is lacking, these undesired effects may range from mild cognitive impairment to disabling psychiatric disorders. However, most recreational and medical users appear to rate the benefits as outweighing the risks in choosing to continue their cannabis use. It should be noted that public health messages to users are distorted, because funding for research is often targeted to studying the harmful effects of cannabis rather than the benefits. Despite studies aiming to document negative effects, occasionally positive effects are noted, such as enhanced divergent thinking following either oral THC or smoked cannabis 24, 157 . Future research should evaluate perceived benefits to give a more balanced understanding; people clearly do not use cannabis only for its harms.
Throughout this Review, we have specified gaps in our knowledge. Although problems associated with cannabis use are mainly observed in heavy, frequent users, we are still not sure what level of use of what type of cannabis is non-problematic. We need such data for harm-reduction advice for both medical and recreational users.
Another question that needs answering is: how does repeated use of cannabis causally affect the human adolescent and adult brain given that most cannabis users also use alcohol, another cognitively impairing drug? A recent comparison of daily cannabis users who also drank alcohol and alcohol-intake-matched, non-using controls in both adolescents and adults found no differences in brain structure between the two groups 158 , but longitudinal data are currently lacking. It is also still unclear exactly how the effects of cannabis vary across clinical populations. For example, a meta-analysis showed that people who are diagnosed with schizophrenia and use cannabis function better cognitively than individuals with schizophrenia who do not use cannabis 159 . Finally, we need to understand more about how variants of the drug produce differential effectsvariants not only in constituent cannabinoids but also in the new synthetic cannabis (such as 'spice') 93 , as well as new forms of administration (for example, through vaping or edible forms) 160 . Future studies will help to fill these gaps of knowledge, especially if they incorporate methodological improvements. Most studies of long-term effects assess level of cannabis use through various self-report measures (such as frequency, years of use and time to smoke a specific amount of the drug) and could benefit from improved biomarkers such as Δ 9 -THC and CBD levels in hair. We need longitudinal studies that follow young people from before puberty (and before drug use), through biologically defined puberty and into adulthood (while monitoring drug use) and again after subsequent abstinence or continued use. Such studies would use a comprehensive range of assessments (including: tests of cognition, motivation, brain function and mental health; biomarkers of different types; and quantities of cannabis or cannabinoids and other recreational substances used) so that the interactions among these factors may be monitored. This need should be addressed by the US National Institutes of Health-funded Adolescent Brain Cognition Development (ABCD) Study: a prospective, 10-year, longitudinal study of 10,000 individuals beginning at 9-10 years of age. This study is designed to assess the impact of substance use on brain development and neurocognitive function through a battery of measures obtained before cannabis use, following use at various levels and again following cessation of use. Given recent changes in the medical and legal status of cannabis in some countries, randomized controlled trials of the effects of different types and doses of cannabis can now be conducted. Work with animals will be important in delineating chronic effects, and studies administering doses and schedules within a human-relevant range (as exemplified in REF. 47 ) are the most helpful.
The number of cannabis addicts may well grow as cannabis use becomes more acceptable and the drug more accessible. Indeed, there is evidence that this is already happening in the United States 161 . We therefore urgently need to increase our efforts to understand what factors influence the development of addiction and build preventive measures against this. Currently, we lack an effective pharmacological treatment for cannabis addiction that can be used conjointly with psychosocial therapies to boost the currently low efficacy of treatment approaches. This need requires urgent research attention.
With hindsight, we can clearly see the enormous problems that have been caused to many individuals and to society by tobacco and alcohol. Unlike cannabis, these drugs are legal in most countries, despite the fact that, if asked to decide today which psychoactive drugs should be legal, cannabis (which rarely kills people) might well be judged as being comparatively benign. Legislative changes would help researchers, as current restrictive drug scheduling markedly hinders neuroscience research and the innovation of psychiatric treatments 162 . More importantly, if handled carefully from a harm-reduction standpoint, a regulated market might increase the control over the age of initiation of use and other vulnerability factors; inform accurately about dosage; and increase the availability of more-balanced cannabis (that is, with lower levels of Δ 9 -THC and higher levels of CBD) to maintain desired effects while reducing the incidence of harms.
